What's Hot
View all perspectives
David Liew drdavidliew
1 year 4 months ago
Dazodalibep is the next CD40L inhibitor being tested in Sjogren’s - we need better therapies genuinely reducing symptom burden. Nice phase 2 data analyses so far of subjective measures, and plenty will be happy if we see this kind of result in phase 3
LB0003 #EULAR2023 @RheumNow https://t.co/HYcXEzswAg
Aurelie Najm AurelieRheumo
1 year 4 months ago
How do we improve MTX adherence?
Biochemical measure of MTX adherence
37% of patients starting a biologic do not take their MTX (!)
Those who do respond better to first Biologic at 6 Mo than those who don’t
37% biologic responders = non adherent
POS0313 #EULAR23 @Rheumnow https://t.co/L1Mkqpg1Aj
Janet Pope Janetbirdope
1 year 4 months ago
A mono therapy study RCT of TLL-018 vs #Tofa in RA subanalyses of previous JAKi exposure have not been done. Pts could have failed #Tofacitinib & enrolled so data could be divided to determine how this group responded. Safety looked good in both Rx LB0001 @RheumNow #EULAR2023 https://t.co/4kBHxWmk0q
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 4 months ago
#EULAR2023 #LB0001 Data from Phase 2 RCT in China showed novel therapy, TLL-018, dual JAK1/Tyk2-i showed superior response to Tofacitinib. Safety profile were similar. Interesting to see data in Phase 3. May be an option for difficult to treat Rheumatoid Arthritis @RheumNow https://t.co/Db5QhzNUC1
Md Yuzaiful Md Yusof Yuz6Yusof
1 year 4 months ago
#EULAR2023 Before the Highlights sessions, do come along to a session on Novel Mechanism of Cell Death at 12 noon Space 3. We have great line up of speakers 👍🏽🙌🏻 https://t.co/ObcC11uxz0
Janet Pope Janetbirdope
1 year 4 months ago
What about a new oral drug in active #rheumatoid #arthritis vs #JAKi #Tofacitinib? TLL-018 a potent JAK1/TYK2 inhibitor was compared with #Tofa and dose ranging of 10, 20, 30 mg of TLL-018 and many Pts w past TNFi and w JAKi. High dose won #EULAR2023 @RheumNow @eular_org LB0001 https://t.co/UXhT7LV1oD
Aurelie Najm AurelieRheumo
1 year 4 months ago
DISSOLVE 1&2
SEL 212 = tolerogenic nanoparticles containing rapamycin (SEL-110) + pegadricase (SEL-037)
Meets primary endpoint in 2 RCTs
High dose response 56% & 46%
97% reduction in sUA
Infusion reaction 4%, stomatitis 8%
Anaphylaxis 4 cases
@RheumNow #EULAR23 LB0002 https://t.co/21HieM7NfC
Day 3 was a sunny warm day in Milan at the 2023 EULAR Congress meeting. Here are a few of my favorite abstracts from today.
A nationwide population-based study, by Beydon et al. (OP0044), has performed a more recent (2010-2020) analysis of cancer incidence in people living with RA within the French national claim database, compared to general population, measured in the French Network of Population-Based Cancer Registries.
Dr. John Cush RheumNow
1 year 4 months ago
#EULAR23 – Day 1 Report
The opening Plenary session and presidential address was followed by a number of overview and review sessions with but a half-day of abstracts presentations, on several therapeutic areas including JIA, COVID and more.
https://t.co/7TayWx8SR6 https://t.co/p1K1MduPmO
The use of artificial intelligence to analyse large data sets using its subset component machine learning has taken centre stage recently in the management of rheumatic conditions, including rheumatoid arthritis. The use of AI is now starting to cross the various stages in patient care from detection, diagnosis, treatment and the prediction of long-term outcome.
Risk of poor pregnancy outcomes in lupus patients continues to remain high, especially in the setting of high disease activity. Preliminary data from a lupus pregnancy LEGACY cohort presented at EULAR 2023 raise concern.
Poster Hall